LOGO.png
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
November 14, 2023 08:00 ET | Nemaura Medical, Inc
Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a...
LOGO.png
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
November 13, 2023 16:14 ET | Nemaura Medical, Inc
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...
LOGO.png
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
September 26, 2023 09:50 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...
LOGO.png
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
September 18, 2023 09:15 ET | Nemaura Medical, Inc
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable...
LOGO.png
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
September 14, 2023 08:00 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...
LOGO.png
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
September 13, 2023 08:00 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...
LOGO.png
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
September 12, 2023 09:26 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...
LOGO.png
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
September 11, 2023 09:00 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
LOGO.png
Nemaura Medical Announces SFDA Approval of sugarBEAT®
August 17, 2023 08:30 ET | Nemaura Medical, Inc
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...
LOGO.png
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update
August 14, 2023 08:30 ET | Nemaura Medical, Inc
Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...